European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
EBAC was delisted on the 2nd of March, 2023.
50 hedge funds and large institutions have $94M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
9% more capital invested
Capital invested by funds: $86.6M → $94M (+$7.44M)
0% more funds holding
Funds holding: 50 → 50 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$2.59M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.5M |
| 3 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
+$999K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$999K |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$952K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.69M |
| 2 |
Calamos Advisors
Naperville,
Illinois
|
-$992K |
| 3 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$959K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$664K |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
BNP Paribas Financial Markets
Paris,
France
| – | -$3.69M | -496,000 | Closed |
|
|
52
Calamos Advisors
Naperville,
Illinois
| – | -$992K | -100,000 | Closed |
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$271 | -27,325 | Closed |
|
|
AA
54
Ancora Advisors
Cleveland,
Ohio
| – | -$69K | -7,000 | Closed |
|
EBAC Hedge Fund Activity: Q4 2022 in Review
50 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q4 2022, worth a combined $94M — up 8.6% from $86.6M a quarter earlier.
Fund positioning in EBAC was balanced in Q4 2022: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Glazer Capital LLC, adding an estimated $2.59M. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $3.69M sold.
- 50 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $94M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q4 2022, up 8.6% quarter-over-quarter.
- 5 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q4 2022 and 5 closed out, a net change of 0 holders.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q4 2022 was Glazer Capital LLC, an estimated $2.59M added.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q4 2022 was BNP Paribas Financial Markets, an estimated $3.69M sold.
Based on aggregated 13F filings for Q4 2022.